Evidence map›Paper›PMID 30201760›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2019

Spatial Architecture and Arrangement of Tumor-Infiltrating Lymphocytes for Predicting Likelihood of Recurrence in Early-Stage Non-Small Cell Lung Cancer.

Germán Corredor, Xiangxue Wang, Yu Zhou, Cheng Lu, Pingfu Fu, Konstantinos Syrigos, David L Rimm, Michael Yang, Eduardo Romero, Kurt A Schalper and 2 more

Abstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 152 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
152citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

152 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Computationally Derived Spatial Immune Signature Identifies Trastuzumab Responders in HER2+ Breast Cancer: NSABP B-41 Clinical Trial Validation.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Trial
  4. Article
  5. Adaptive resistance in cancer immunotherapy.Cellular & molecular immunology · 2026
    Review
  6. Article
  7. Article
  8. Article
  9. A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

92 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Germán Corredor *Center for Computational Imaging and Personalized Diagnostics, Case Western Reserve University, Cleveland, Ohio.
Xiangxue Wang *Center for Computational Imaging and Personalized Diagnostics, Case Western Reserve University, Cleveland, Ohio.
Yu ZhouCenter for Computational Imaging and Personalized Diagnostics, Case Western Reserve University, Cleveland, Ohio.
Cheng LuCenter for Computational Imaging and Personalized Diagnostics, Case Western Reserve University, Cleveland, Ohio.
Pingfu FuDepartment of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, Ohio.ORCID 0000-0002-2334-5218
Konstantinos SyrigosDepartment of Medicine, University of Athens, Sotiria General Hospital, Athens, Greece.
David L RimmDepartment of Pathology, Yale University School of Medicine, New Haven, Connecticut.
Michael YangDepartment of Pathology-Anatomic, University Hospitals, Cleveland, Ohio.
Eduardo RomeroComputer Imaging and Medical Applications Laboratory, Universidad Nacional de Colombia, Bogotá, Colombia.
Kurt A SchalperDepartment of Pathology, Yale University School of Medicine, New Haven, Connecticut.
Vamsidhar VelchetiHematology and Medical Oncology Department, Cleveland Clinic, Cleveland, Ohio.
Anant MadabhushiCenter for Computational Imaging and Personalized Diagnostics, Case Western Reserve University, Cleveland, Ohio. axm788@case.edu.ORCID 0000-0002-5741-0399

Funding

Oral Cavity Quantitative Histomorphometric Risk Classifier (OHbIC) in Oral Cavity Squamous Cell Carcinoma (OC-SCC)R01CA249992 · NCI · EMORY UNIVERSITY · PI LEWIS, JAMES, MADABHUSHI, ANANT · 2021 to 2025
$3.2M
Computerized histologic image predictor of cancer outcomeR01CA202752 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI FELDMAN, MICHAEL D, GANESAN, SHRIDAR · 2016 to 2020
$3.1M
Quantitative Histomorphometric Risk Classifier (QuHbIC) in HPV + Oropharyngeal CarcinomaR01CA220581 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI KOYFMAN, SHLOMO, LEWIS, JAMES · 2018 to 2023
$3.1M
Computerized Histologic Risk Predictor (CHiRP) for Early Stage Lung CancersR01CA216579 · NCI · EMORY UNIVERSITY · PI FU, PINGFU, LLOYD, MARK · 2018 to 2023
$3.1M
MR Fingerprinting and Computerized Decision Support for Prostate CancerR01CA208236 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GULANI, VIKAS, PONSKY, LEE EVAN · 2017 to 2022
$3.0M
Pathology Image Informatics Platform for visualization, analysis and managementU24CA199374 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI GURCAN, METIN NAFI, MADABHUSHI, ANANT · 2015 to 2019
$2.9M
RadIO: A Novel Radiomics Toolkit to Predict and Characterize Response to Immunotherapy in Stage III Non-Small Cell Lung CancerI01BX004121 · VA · VETERANS HEALTH ADMINISTRATION · PI Anant Madabhushi, Charles J Nock · 2019 to 2026
–
BIOMEDICAL ENGINEERING RESEARCH FACILITIESC06RR012463 · NCRR · CASE WESTERN RESERVE UNIVERSITY · PI KUTINA, KENNETH L · 1997 to 1997
–
BLRD VA I01 BX004121NCI NIH HHS R01 CA202752NCI NIH HHS R01 CA208236NCI NIH HHS R01 CA216579NCI NIH HHS R01 CA220581NCI NIH HHS R01 CA249992NCI NIH HHS U24 CA199374NCRR NIH HHS C06 RR012463
6 · The paper itself

Abstract

purposeThe presence of a high degree of tumor-infiltrating lymphocytes (TIL) has been proven to be associated with outcome in patients with non-small cell lung cancer (NSCLC). However, recent evidence indicates that tissue architecture is also prognostic of disease-specific survival and recurrence. We show a set of descriptors (spatial TIL, SpaTIL) that capture density, and spatial colocalization of TILs and tumor cells across digital images that can predict likelihood of recurrence in early-stage NSCLC. EXPERIMENTAL

designThe association between recurrence in early-stage NSCLC and SpaTIL features was explored on 301 patients across four different cohorts. Cohort D

resultsSpaTIL was associated with likelihood of recurrence in all test sets (log-rank

conclusionsA set of features related to density and spatial architecture of TILs was found to be associated with a likelihood of recurrence of early-stage NSCLC. This information could potentially be used for helping in treatment planning and management of early-stage NSCLC.

Indexed as

AgedCarcinoma, Non-Small-Cell LungFemaleHumansLung NeoplasmsLymphocytes, Tumor-InfiltratingMaleMiddle AgedNeoplasm MetastasisNeoplasm StagingPrognosisProportional Hazards ModelsRecurrence

Identifiers

PMID30201760
PMCPMC6397708

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.